메뉴 건너뛰기




Volumn 6, Issue 6, 2013, Pages 651-662

Beyond humanization and de-immunization: Tolerization as a method for reducing the immunogenicity of biologics

Author keywords

alemtuzumab; bio better; biologic; biosimilar; Campath ; immunogenicity; mAb; monoclonal; quality by design; tolerance; tregitope

Indexed keywords

ALEMTUZUMAB; BOTULINUM TOXIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; GLUCAN 1,4 ALPHA GLUCOSIDASE; LYSOSTAPHIN; RITUXIMAB; STAPHYLOKINASE;

EID: 84887283047     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2013.835698     Document Type: Review
Times cited : (37)

References (86)
  • 2
  • 3
    • 40449085408 scopus 로고    scopus 로고
    • Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model
    • Joseph A, Munroe K, Housman M, Garman R, Richards S. Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model. Clin. Exp. Immunol. 152(1), 138-146 (2008).
    • (2008) Clin. Exp. Immunol. , vol.152 , Issue.1 , pp. 138-146
    • Joseph, A.1    Munroe, K.2    Housman, M.3    Garman, R.4    Richards, S.5
  • 4
    • 84855542158 scopus 로고    scopus 로고
    • Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease
    • Messinger YH, Mendelsohn NJ, Rhead W et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet. Med. 14(1), 135-142 (2012).
    • (2012) Genet. Med. , vol.14 , Issue.1 , pp. 135-142
    • Messinger, Y.H.1    Mendelsohn, N.J.2    Rhead, W.3
  • 5
    • 66749108874 scopus 로고    scopus 로고
    • Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy
    • Kubisz P, Plamenová I, Hollý P, Stasko J. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy. Med. Sci. Monit. 15(6), CS105-CS111 (2009).
    • (2009) Med. Sci. Monit. , vol.15 , Issue.6
    • Kubisz, P.1    Plamenová, I.2    Hollý, P.3    Stasko, J.4
  • 6
    • 0036277088 scopus 로고    scopus 로고
    • A personal history of the CAMPATH-1H antibody
    • Waldmann H. A personal history of the CAMPATH-1H antibody. Med. Oncol. 19 (Suppl.), S3-S9 (2002).
    • (2002) Med. Oncol. , vol.19 , Issue.SUPPL.
    • Waldmann, H.1
  • 8
    • 77957361348 scopus 로고    scopus 로고
    • Development trends for human monoclonal antibody therapeutics
    • Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9(10), 767-774 (2010).
    • (2010) Nat. Rev. Drug Discov. , vol.9 , Issue.10 , pp. 767-774
    • Nelson, A.L.1    Dhimolea, E.2    Reichert, J.M.3
  • 10
    • 0033866627 scopus 로고    scopus 로고
    • Antibody humanization: A case of the 'Emperor's new clothes'? Immunol
    • Clark M. Antibody humanization: a case of the 'Emperor's new clothes'? Immunol. Today 21(8), 397-402 (2000).
    • (2000) Today , vol.21 , Issue.8 , pp. 397-402
    • Clark, M.1
  • 11
    • 54049088585 scopus 로고    scopus 로고
    • Activation of natural regulatory T cells by IgG Fc-derived peptide "tregitopes"
    • De Groot AS, Moise L, McMurry JA et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112(8), 3303-3311 (2008).
    • (2008) Blood , vol.112 , Issue.8 , pp. 3303-3311
    • De Groot, A.S.1    Moise, L.2    McMurry, J.A.3
  • 12
    • 63749128279 scopus 로고    scopus 로고
    • Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics
    • De Groot AS, Martin W. Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics. Clin. Immunol. 131(2), 189-201 (2009).
    • (2009) Clin. Immunol. , vol.131 , Issue.2 , pp. 189-201
    • De Groot, A.S.1    Martin, W.2
  • 13
    • 84880992500 scopus 로고    scopus 로고
    • Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se
    • Su Y, Rossi R, De Groot AS, Scott DW. Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. J. Leukoc. Biol. 94(2), 377-383 (2013).
    • (2013) J. Leukoc. Biol. , vol.94 , Issue.2 , pp. 377-383
    • Su, Y.1    Rossi, R.2    De Groot, A.S.3    Scott, D.W.4
  • 14
    • 84872616027 scopus 로고    scopus 로고
    • In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): A promising new tool for tolerance induction and treatment of autoimmunity
    • Cousens LP, Najafian N, Mingozzi F et al. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): A promising new tool for tolerance induction and treatment of autoimmunity. J. Clin. Immunol. 33(1), 43-49 (2013).
    • (2013) J. Clin. Immunol. , vol.33 , Issue.1 , pp. 43-49
    • Cousens, L.P.1    Najafian, N.2    Mingozzi, F.3
  • 15
    • 77953658260 scopus 로고    scopus 로고
    • The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions
    • Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. mAbs. 2(3), 256-265 (2010).
    • (2010) MAbs. , vol.2 , Issue.3 , pp. 256-265
    • Harding, F.A.1    Stickler, M.M.2    Razo, J.3    Dubridge, R.B.4
  • 16
    • 0030008601 scopus 로고    scopus 로고
    • Detection of IGA anti-OKT3 antibodies in OKT3-treated transplant recipients
    • McIntyre JA, Kincade M, Higgins NG. Detection of IGA anti-OKT3 antibodies in OKT3-treated transplant recipients. Transplantation 61(10), 1465-1469 (1996).
    • (1996) Transplantation , vol.61 , Issue.10 , pp. 1465-1469
    • McIntyre, J.A.1    Kincade, M.2    Higgins, N.G.3
  • 17
    • 0033387144 scopus 로고    scopus 로고
    • Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor
    • Uckun FM, Messinger Y, Chen CL et al. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin. Cancer Res. 5(12), 3906-3913 (1999).
    • (1999) Clin. Cancer Res. , vol.5 , Issue.12 , pp. 3906-3913
    • Uckun, F.M.1    Messinger, Y.2    Chen, C.L.3
  • 18
    • 0035478728 scopus 로고    scopus 로고
    • Pivotal study of iodine i 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
    • Kaminski MS, Zelenetz AD, Press OW et al . Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol. 19(19), 3918-3928 (2001).
    • (2001) J. Clin. Oncol. , vol.19 , Issue.19 , pp. 3918-3928
    • Kaminski, M.S.1    Zelenetz, A.D.2    Press, O.W.3
  • 19
    • 0033624181 scopus 로고    scopus 로고
    • Safety and biodistribution of 99mTechnetium-labeled anti- CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients
    • Stroomer JW, Roos JC, Sproll M et al. Safety and biodistribution of 99mTechnetium-labeled anti- CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin. Cancer Res. 6(8), 3046-3055 (2000).
    • (2000) Clin. Cancer Res. , vol.6 , Issue.8 , pp. 3046-3055
    • Stroomer, J.W.1    Roos, J.C.2    Sproll, M.3
  • 20
    • 0033855660 scopus 로고    scopus 로고
    • Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment
    • Davis TA, Grillo-López AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18(17), 3135-3143 (2000).
    • (2000) J. Clin. Oncol. , vol.18 , Issue.17 , pp. 3135-3143
    • Davis, T.A.1    Grillo-López, A.J.2    White, C.A.3
  • 21
    • 0032791210 scopus 로고    scopus 로고
    • Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
    • Piro LD, White CA, Grillo-López AJ et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol. 10(6), 655-661 (1999).
    • (1999) Ann. Oncol. , vol.10 , Issue.6 , pp. 655-661
    • Piro, L.D.1    White, C.A.2    Grillo-López, A.J.3
  • 22
    • 25444437442 scopus 로고    scopus 로고
    • Rituximab treatment in patients with primary Sjögren's syndrome: An open-label phase II study
    • Pijpe J, van Imhoff GW, Spijkervet FK et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum. 52(9), 2740-2750 (2005).
    • (2005) Arthritis Rheum. , vol.52 , Issue.9 , pp. 2740-2750
    • Pijpe, J.1    Van Imhoff, G.W.2    Spijkervet, F.K.3
  • 23
    • 4043179907 scopus 로고    scopus 로고
    • B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab
    • Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50(8), 2580-2589 (2004).
    • (2004) Arthritis Rheum. , vol.50 , Issue.8 , pp. 2580-2589
    • Looney, R.J.1    Anolik, J.H.2    Campbell, D.3
  • 24
    • 84867838679 scopus 로고    scopus 로고
    • Humanization by CDR grafting and specificity-determining residue grafting
    • M Kim JH, Hong HJ. Humanization by CDR grafting and specificity- determining residue grafting. Methods Mol. Biol. 907, 237-245 (2012).
    • (2012) Methods Mol. Biol. , vol.907 , pp. 237-245
    • Kim, J.H.M.1    Hong, H.J.2
  • 25
    • 0041303578 scopus 로고    scopus 로고
    • Immunogenicity of biological therapeutics: A hierarchy of concerns
    • Rosenberg AS. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev. Biol. (Basel) 112, 15-21 (2003).
    • (2003) Dev. Biol. (Basel) , vol.112 , pp. 15-21
    • Rosenberg, A.S.1
  • 26
    • 79953681018 scopus 로고    scopus 로고
    • Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters
    • Barbosa MD. Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters. Drug Discov. Today 16, 345-353 (2011).
    • (2011) Drug Discov. Today , vol.16 , pp. 345-353
    • Barbosa, M.D.1
  • 27
    • 84879975984 scopus 로고    scopus 로고
    • Drug monitoring of biologics in inflammatory bowel disease
    • Eser A, Primas C, Reinisch W. Drug monitoring of biologics in inflammatory bowel disease. Curr. Opin. Gastroenterol. 29(4), 391-396 (2013).
    • (2013) Curr. Opin. Gastroenterol. , vol.29 , Issue.4 , pp. 391-396
    • Eser, A.1    Primas, C.2    Reinisch, W.3
  • 28
    • 34249684926 scopus 로고    scopus 로고
    • A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
    • Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25, 555-561 (2007).
    • (2007) Nat. Biotechnol. , vol.25 , pp. 555-561
    • Shankar, G.1    Pendley, C.2    Stein, K.E.3
  • 29
    • 0042510222 scopus 로고    scopus 로고
    • Epoetins: Differences and their relevance to immunogenicity
    • Haselbeck A. Epoetins: differences and their relevance to immunogenicity. Curr. Med. Res. Opin. 19(5), 430-432 (2003).
    • (2003) Curr. Med. Res. Opin. , vol.19 , Issue.5 , pp. 430-432
    • Haselbeck, A.1
  • 30
    • 0038752054 scopus 로고    scopus 로고
    • Pure red-cell aplasia due to anti-erythropoietin antibodies
    • Eckardt KU, Casadevall N. Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol. Dial. Transplant 18, 865-869 (2003).
    • (2003) Nephrol. Dial. Transplant , vol.18 , pp. 865-869
    • Eckardt, K.U.1    Casadevall, N.2
  • 31
    • 0347297138 scopus 로고    scopus 로고
    • A threshold for central T cell tolerance to an inducible serum 870 protein
    • Haribhai D, Engle D, Meyer M et al. A threshold for central T cell tolerance to an inducible serum 870 protein. J. Immunol. 170(6), 3007-3014 (2003).
    • (2003) J. Immunol. , vol.170 , Issue.6 , pp. 3007-3014
    • Haribhai, D.1    Engle, D.2    Meyer, M.3
  • 33
    • 4344627627 scopus 로고    scopus 로고
    • Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease
    • Garman RD, Munroe K, Richards SM. Methotrexate reduces antibody responses to recombinant human alpha-galactosidase A therapy in a mouse model of Fabry disease. Clin. Exp. Immunol. 137(3), 496-502 (2004).
    • (2004) Clin. Exp. Immunol. , vol.137 , Issue.3 , pp. 496-502
    • Garman, R.D.1    Munroe, K.2    Richards, S.M.3
  • 34
    • 77956613455 scopus 로고    scopus 로고
    • Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics
    • Wullner D, Zhou L, Bramhall E et al. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin. Immunol. 137(1), 5-14 (2010).
    • (2010) Clin. Immunol. , vol.137 , Issue.1 , pp. 5-14
    • Wullner, D.1    Zhou, L.2    Bramhall, E.3
  • 35
    • 29444451997 scopus 로고    scopus 로고
    • Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity
    • Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin. Immunol. 118, 42-50 (2006).
    • (2006) Clin. Immunol. , vol.118 , pp. 42-50
    • Barbosa, M.D.1    Vielmetter, J.2    Chu, S.3    Smith, D.D.4    Jacinto, J.5
  • 37
    • 42949139524 scopus 로고    scopus 로고
    • A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach
    • Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput. Biol. 4(4), e1000048 (2008).
    • (2008) PLoS Comput. Biol. , vol.4 , Issue.4
    • Wang, P.1    Sidney, J.2    Dow, C.3    Mothé, B.4    Sette, A.5    Peters, B.6
  • 38
    • 34249010944 scopus 로고    scopus 로고
    • Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein
    • Koren E, De Groot AS, Jawa V et al. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin. Immunol. 124(1), 25-32 (2007).
    • (2007) Clin. Immunol. , vol.124 , Issue.1 , pp. 25-32
    • Koren, E.1    De Groot, A.S.2    Jawa, V.3
  • 39
    • 77955364125 scopus 로고    scopus 로고
    • A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: Individualized T cell epitope measure (iTEM)
    • Cohen T, Moise L, Ardito M, Martin W, De Groot AS. A method for individualizing the prediction of immunogenicity of protein vaccines and biologic therapeutics: individualized T cell epitope measure (iTEM). J. Biomed. Biotechnol. 7 (2010).
    • (2010) J. Biomed. Biotechnol. , vol.7
    • Cohen, T.1    Moise, L.2    Ardito, M.3    Martin, W.4    De Groot, A.S.5
  • 40
    • 39649109499 scopus 로고    scopus 로고
    • Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion
    • Tatarewicz SM, Wei X, Gupta S, Masterman D, Swanson SJ, Moxness MS. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J. Clin. Immunol. 27(6), 620-627 (2007).
    • (2007) J. Clin. Immunol. , vol.27 , Issue.6 , pp. 620-627
    • Tatarewicz, S.M.1    Wei, X.2    Gupta, S.3    Masterman, D.4    Swanson, S.J.5    Moxness, M.S.6
  • 42
    • 0028295047 scopus 로고
    • Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins
    • Kast WM, Brandt RM, Sidney J et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J. Immunol. 152, 3904-3912 (1994).
    • (1994) J. Immunol. , vol.152 , pp. 3904-3912
    • Kast, W.M.1    Brandt, R.M.2    Sidney, J.3
  • 43
    • 0032210911 scopus 로고    scopus 로고
    • Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix
    • Schafer JR, Jesdale BM, George JA, Kouttab NM, De Groot AS. Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine 16(19), 1880-1884 (1998).
    • (1998) Vaccine , vol.16 , Issue.19 , pp. 1880-1884
    • Schafer, J.R.1    Jesdale, B.M.2    George, J.A.3    Kouttab, N.M.4    De Groot, A.S.5
  • 44
    • 0035859982 scopus 로고    scopus 로고
    • From genome to vaccine: In silico predictions, ex vivo verification
    • De Groot AS, Bosma A, Chinai N et al. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 19(31), 4385-4395 (2001).
    • (2001) Vaccine , vol.19 , Issue.31 , pp. 4385-4395
    • De Groot, A.S.1    Bosma, A.2    Chinai, N.3
  • 46
    • 33746132748 scopus 로고    scopus 로고
    • A consensus epitope prediction approach identifies the breadth of murine T(CD8+)- cell responses to vaccinia virus
    • Moutaftsi M, Peters B, Pasquetto V et al. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)- cell responses to vaccinia virus. Nat. Biotechnol. 24(7), 817-819 (2006).
    • (2006) Nat. Biotechnol. , vol.24 , Issue.7 , pp. 817-819
    • Moutaftsi, M.1    Peters, B.2    Pasquetto, V.3
  • 50
    • 33644634447 scopus 로고    scopus 로고
    • De-immunization of therapeutic proteins by T-cell epitope modification
    • De Groot AS, Knopf PM, Martin W. De-immunization of therapeutic proteins by T-cell epitope modification. Dev. Biol. (Basel) 122, 171-194 (2005).
    • (2005) Dev. Biol. (Basel) , vol.122 , pp. 171-194
    • De Groot, A.S.1    Knopf, P.M.2    Martin, W.3
  • 51
    • 84887281859 scopus 로고    scopus 로고
    • Immunogenic biologics: Validation of screening, deimmunization and tolerization approaches (P3251)
    • Cousens L, Moise L, Terry F, Martin W, De Groot AS. Immunogenic biologics: validation of screening, deimmunization and tolerization approaches (P3251). J. Immunol. 190, 192 (2013).
    • (2013) J. Immunol. , vol.190 , pp. 192
    • Cousens, L.1    Moise, L.2    Terry, F.3    Martin, W.4    De Groot, A.S.5
  • 53
    • 0035063692 scopus 로고    scopus 로고
    • Challenges to the development of antigen-specific breast cancer vaccines
    • Scanlan MJ, Jager D. Challenges to the development of antigen-specific breast cancer vaccines. Breast Cancer Res. 3(2), 95-98 (2001).
    • (2001) Breast Cancer Res. , vol.3 , Issue.2 , pp. 95-98
    • Scanlan, M.J.1    Jager, D.2
  • 54
    • 0026691509 scopus 로고
    • Viral escape from immune recognition: Multiple strategies of adenoviruses
    • Mullbacher A. Viral escape from immune recognition: multiple strategies of adenoviruses. Immunol. Cell Biol. 70(Pt 1), 59-63 (1992).
    • (1992) Immunol. Cell Biol. , vol.70 , Issue.PART 1 , pp. 59-63
    • Mullbacher, A.1
  • 57
    • 23844439692 scopus 로고    scopus 로고
    • Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII
    • Jones TD, Phillips WJ, Smith BJ et al. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J. Thromb. Haemost. 3, 991-1000 (2005).
    • (2005) J. Thromb. Haemost. , vol.3 , pp. 991-1000
    • Jones, T.D.1    Phillips, W.J.2    Smith, B.J.3
  • 58
    • 0032812899 scopus 로고    scopus 로고
    • Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes
    • Gilles JG, Lavend'homme R, Peerlinck K et al. Some factor VIII (FVIII) inhibitors recognise a FVIII epitope(s) that is present only on FVIII-vWF complexes. Thromb. Haemost. 82, 40-45 (1999).
    • (1999) Thromb. Haemost. , vol.82 , pp. 40-45
    • Gilles, J.G.1    Lavend'Homme, R.2    Peerlinck, K.3
  • 60
    • 20144384746 scopus 로고    scopus 로고
    • Rationally engineered therapeutic proteins with reduced immunogenicity
    • Tangri S, Mothe BR, Eisenbraun J et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174(6), 3187-3196 (2005).
    • (2005) J. Immunol. , vol.174 , Issue.6 , pp. 3187-3196
    • Tangri, S.1    Mothe, B.R.2    Eisenbraun, J.3
  • 61
    • 2442661578 scopus 로고    scopus 로고
    • Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope
    • Yeung VP, Chang J, Miller J, Barnett C, Stickler M, Harding FA. Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J. Immunol. 172(11), 6658-6665 (2004).
    • (2004) J. Immunol. , vol.172 , Issue.11 , pp. 6658-6665
    • Yeung, V.P.1    Chang, J.2    Miller, J.3    Barnett, C.4    Stickler, M.5    Harding, F.A.6
  • 62
    • 0036218529 scopus 로고    scopus 로고
    • Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling
    • Warmerdam PA, Plaisance S, Vanderlick K et al. Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Thromb. Haemost. 87(4), 666-673 (2002).
    • (2002) Thromb. Haemost. , vol.87 , Issue.4 , pp. 666-673
    • Warmerdam, P.A.1    Plaisance, S.2    Vanderlick, K.3
  • 64
    • 84880911013 scopus 로고    scopus 로고
    • The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix
    • Moise L, Gutierrez AH, Bailey-Kellogg C et al. The two-faced T cell epitope: examining the host-microbe interface with JanusMatrix. Hum. Vaccin. Immunother. 9(7), 1577-1586 (2012).
    • (2012) Hum. Vaccin. Immunother. , vol.9 , Issue.7 , pp. 1577-1586
    • Moise, L.1    Gutierrez, A.H.2    Bailey-Kellogg, C.3
  • 65
    • 84878135799 scopus 로고    scopus 로고
    • Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes
    • Cousens LP, Su Y, McClaine E et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J. Diabetes Res. 621693 (2013).
    • (2013) J. Diabetes Res. , pp. 621693
    • Cousens, L.P.1    Su, Y.2    McClaine, E.3
  • 66
    • 84883741462 scopus 로고    scopus 로고
    • Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes
    • doi:10.1038/ mt.2013.166 (Epub ahead of print).
    • Hui DJ, Basner-Tschakarjan E, Chen Y et al. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Mol. Ther. doi:10.1038/ mt.2013.166 (2013) (Epub ahead of print).
    • (2013) Mol. Ther.
    • Hui, D.J.1    Basner-Tschakarjan, E.2    Chen, Y.3
  • 68
    • 79958264390 scopus 로고    scopus 로고
    • Vaccination with patient-specific tumorderived antigen in first remission improves disease-free survival in follicular lymphoma
    • Schuster SJ, Neelapu SS, Gause BL et al. Vaccination with patient-specific tumorderived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29(20), 2787-2794 (2011).
    • (2011) J. Clin. Oncol. , vol.29 , Issue.20 , pp. 2787-2794
    • Schuster, S.J.1    Neelapu, S.S.2    Gause, B.L.3
  • 69
    • 38349191376 scopus 로고    scopus 로고
    • Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: A critical factor in controlling experimental autoimmune encephalomyelitis
    • Ephrem A, Chamat S, Miquel C et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111(2), 715-722 (2008).
    • (2008) Blood , vol.111 , Issue.2 , pp. 715-722
    • Ephrem, A.1    Chamat, S.2    Miquel, C.3
  • 70
    • 84860751767 scopus 로고    scopus 로고
    • High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis
    • Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K. High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis. J. Rheumatol. 39(5), 1019-1025 (2012).
    • (2012) J. Rheumatol. , vol.39 , Issue.5 , pp. 1019-1025
    • Tsurikisawa, N.1    Saito, H.2    Oshikata, C.3    Tsuburai, T.4    Akiyama, K.5
  • 71
    • 33749259809 scopus 로고    scopus 로고
    • A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+CD25+Foxp3+ regulatory T cells
    • Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J. Am. Soc. Nephrol. 17(10), 2844-2853 (2006).
    • (2006) J. Am. Soc. Nephrol. , vol.17 , Issue.10 , pp. 2844-2853
    • Lopez, M.1    Clarkson, M.R.2    Albin, M.3    Sayegh, M.H.4    Najafian, N.5
  • 72
    • 84875410765 scopus 로고    scopus 로고
    • Intravenous immunoglobulin therapy: How does IgG modulate the immune system? Nat
    • Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat. Rev. Immunol. 13(3), 176-89 (2013).
    • (2013) Rev. Immunol. , vol.13 , Issue.3 , pp. 176-89
    • Schwab, I.1    Nimmerjahn, F.2
  • 73
    • 84883268937 scopus 로고    scopus 로고
    • Immune responses to AAV vectors: Overcoming barriers to successful gene therapy
    • Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122(1), 23-36 (2013).
    • (2013) Blood , vol.122 , Issue.1 , pp. 23-36
    • Mingozzi, F.1    High, K.A.2
  • 74
    • 84886245403 scopus 로고    scopus 로고
    • Tolerance induction in hemophilia A animal models: Battling inhibitors with antigen-specific immunotherapies
    • Adair P, Su Y, Scott DW. Tolerance induction in hemophilia A animal models: battling inhibitors with antigen-specific immunotherapies. Discov. Med. 15(84), 275-282 (2013).
    • (2013) Discov. Med. , vol.15 , Issue.84 , pp. 275-282
    • Adair, P.1    Su, Y.2    Scott, D.W.3
  • 75
    • 0037364804 scopus 로고    scopus 로고
    • Natural versus adaptive regulatory T cells
    • Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3, 253-257 (2003).
    • (2003) Nat. Rev. Immunol. , vol.3 , pp. 253-257
    • Bluestone, J.A.1    Abbas, A.K.2
  • 76
    • 84862270750 scopus 로고    scopus 로고
    • Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy)
    • Bakacs T, Mehrishi JN, Szabo M, Moss RW. Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy). Pharmacol. Res. 66(2), 192-197 (2012).
    • (2012) Pharmacol. Res. , vol.66 , Issue.2 , pp. 192-197
    • Bakacs, T.1    Mehrishi, J.N.2    Szabo, M.3    Moss, R.W.4
  • 77
    • 0022502731 scopus 로고
    • Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function
    • Baxevanis CN, Ioannides CG, Reclos GJ, Papamichail M. Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function. Eur. J. Immunol. 16, 1013-1016 (1986).
    • (1986) Eur. J. Immunol. , vol.16 , pp. 1013-1016
    • Baxevanis, C.N.1    Ioannides, C.G.2    Reclos, G.J.3    Papamichail, M.4
  • 78
    • 0029995883 scopus 로고    scopus 로고
    • Epitope-specific tolerance induction with an engineered immunoglobulin
    • Zambidis ET, Scott DW. Epitope-specific tolerance induction with an engineered immunoglobulin. Proc. Natl Acad. Sci. U.S. A. 93, 5019-5024 (1996).
    • (1996) Proc. Natl Acad. Sci. U.S. A. , vol.93 , pp. 5019-5024
    • Zambidis, E.T.1    Scott, D.W.2
  • 80
    • 33751106428 scopus 로고    scopus 로고
    • IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris
    • Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 39(70), 601-607 (2006).
    • (2006) Autoimmunity , vol.39 , Issue.70 , pp. 601-607
    • Bystryn, J.C.1    Jiao, D.2
  • 81
    • 33644927503 scopus 로고    scopus 로고
    • Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients
    • Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am. J. Transplant. 6(3), 459-466 (2006).
    • (2006) Am. J. Transplant. , vol.6 , Issue.3 , pp. 459-466
    • Jordan, S.C.1    Vo, A.A.2    Peng, A.3    Toyoda, M.4    Tyan, D.5
  • 82
    • 84878344070 scopus 로고    scopus 로고
    • Alemtuzumab treatment of multiple sclerosis
    • Coles AJ. Alemtuzumab treatment of multiple sclerosis. Semin. Neurol. 33(1), 66-73 (2013).
    • (2013) Semin. Neurol. , vol.33 , Issue.1 , pp. 66-73
    • Coles, A.J.1
  • 83
    • 77956209762 scopus 로고    scopus 로고
    • A novel strategy to reduce the immunogenicity of biological therapies
    • Somerfield J, Hill-Cawthorne GA, Lin A et al. A novel strategy to reduce the immunogenicity of biological therapies. J. Immunol. 185(1), 763-768 (2010).
    • (2010) J. Immunol. , vol.185 , Issue.1 , pp. 763-768
    • Somerfield, J.1    Hill-Cawthorne, G.A.2    Lin, A.3
  • 84
    • 0026783632 scopus 로고
    • Humanised monoclonal antibody therapy for rheumatoid arthritis
    • Isaacs JD, Watts RA, Hazleman BL et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340(8822), 748-752 (1992).
    • (1992) Lancet , vol.340 , Issue.8822 , pp. 748-752
    • Isaacs, J.D.1    Watts, R.A.2    Hazleman, B.L.3
  • 85
    • 0029875268 scopus 로고    scopus 로고
    • CAMPATH-1H in rheumatoid arthritis: An intravenous dose-ranging study
    • Isaacs JD, Manna VK, Rapson N et al. CAMPATH-1H in rheumatoid arthritis: an intravenous dose-ranging study. Br. J. Rheumatol. 35(3), 231-240 (1996).
    • (1996) Br. J. Rheumatol. , vol.35 , Issue.3 , pp. 231-240
    • Isaacs, J.D.1    Manna, V.K.2    Rapson, N.3
  • 86
    • 0029143898 scopus 로고
    • Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection
    • Matteson EL, Yocum DE, St Clair EW et al. Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody CAMPATH-1H administered by daily subcutaneous injection. Arthritis Rheum. 38(9), 1187-1193 (1995).
    • (1995) Arthritis Rheum. , vol.38 , Issue.9 , pp. 1187-1193
    • Matteson, E.L.1    Yocum, D.E.2    St Clair, E.W.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.